Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Top Cited Papers
Open Access
- 5 March 2015
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 45 (5), 1434-1445
- https://doi.org/10.1183/09031936.00174914
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic pathways involved in IPF have not been fully elucidated, IPF is believed to be caused by repetitive alveolar epithelial cell injury and dysregulated repair, in which there is uncontrolled proliferation of lung fibroblasts and differentiation of fibroblasts into myofibroblasts, which excessively deposit extracellular matrix (ECM) proteins in the interstitial space. A number of profibrotic mediators including platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-β are believed to play important roles in the pathogenesis of IPF. Nintedanib is a potent small molecule inhibitor of the receptor tyrosine kinases PDGF receptor, FGF receptor and vascular endothelial growth factor receptor. Data from in vitro studies have shown that nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation, and the secretion of ECM. In addition, nintedanib has shown consistent anti-fibrotic and anti-inflammatory activity in animal models of lung fibrosis. These data provide a strong rationale for the clinical efficacy of nintedanib in patients with IPF, which has recently been demonstrated in phase III clinical trials.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 84 references indexed in Scilit:
- Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transitionProceedings of the National Academy of Sciences of the United States of America, 2011
- Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Overexpression of Fibroblast Growth Factor-10 during Both Inflammatory and Fibrotic Phases Attenuates Bleomycin-induced Pulmonary Fibrosis in MiceAmerican Journal of Respiratory and Critical Care Medicine, 2009
- VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in ratsJCI Insight, 2009
- Vascular endothelial growth factor of the lung: friend or foeCurrent Opinion in Pharmacology, 2008
- Vascular endothelial growth factor can signal through platelet-derived growth factor receptorsThe Journal of cell biology, 2007
- IMATINIB MESYLATE INHIBITS FIBROGENESIS IN ASBESTOS-INDUCED INTERSTITIAL PNEUMONIAExperimental Lung Research, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003